[go: up one dir, main page]

AR121187A1 - Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene - Google Patents

Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene

Info

Publication number
AR121187A1
AR121187A1 ARP200103637A ARP200103637A AR121187A1 AR 121187 A1 AR121187 A1 AR 121187A1 AR P200103637 A ARP200103637 A AR P200103637A AR P200103637 A ARP200103637 A AR P200103637A AR 121187 A1 AR121187 A1 AR 121187A1
Authority
AR
Argentina
Prior art keywords
formulation
raw material
pharmaceutical
sodium lauryl
lauryl sulfate
Prior art date
Application number
ARP200103637A
Other languages
English (en)
Inventor
Takuro SASAYAMA
Yoshiko KURE
Tadanobu Nakayama
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR121187A1 publication Critical patent/AR121187A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/2055—Analysing diffraction patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/025—Gas chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/085—Analysis of materials for the purpose of controlling industrial production systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente proporciona un método para determinar un lauril sulfato de sodio que tiene una calidad deseada como materia prima farmacéutica para una formulación mediante la detección de una ligera diferencia en la calidad del lauril sulfato de sodio que se usará como materia prima farmacéutica para una formulación. La presente se refiere a un método para clasificar una materia prima para una formulación que puede proporcionar una formulación farmacéutica de excelente estabilidad mediante el pretratamiento del material para una formulación bajo una condición acelerada predeterminada y detectar una impureza. Según el método de la presente, es posible determinar la calidad del lauril sulfato de sodio de una materia prima farmacéutica para una formulación que no tiene efecto en la calidad de una formulación farmacéutica que contiene alectinib o una sal de este. Una composición farmacéutica producida mediante el uso de una materia prima farmacéutica para una formulación (SLS) y clasificada por el método de la presente puede proporcionar una formulación farmacéutica de alta calidad que tiene excelente estabilidad.
ARP200103637A 2019-12-27 2020-12-23 Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene AR121187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019239018 2019-12-27

Publications (1)

Publication Number Publication Date
AR121187A1 true AR121187A1 (es) 2022-04-27

Family

ID=76575960

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103637A AR121187A1 (es) 2019-12-27 2020-12-23 Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene

Country Status (13)

Country Link
US (1) US20240100058A1 (es)
EP (1) EP4082578A4 (es)
JP (1) JPWO2021132541A1 (es)
KR (1) KR20220119605A (es)
CN (1) CN114786727B (es)
AR (1) AR121187A1 (es)
AU (1) AU2020411954A1 (es)
BR (1) BR112022007093A2 (es)
CA (1) CA3158342A1 (es)
IL (1) IL293995A (es)
MX (1) MX2022007786A (es)
TW (1) TW202135827A (es)
WO (1) WO2021132541A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS492928B1 (es) 1969-11-25 1974-01-23
JPS4918630B1 (es) 1970-07-29 1974-05-11
EP1300160B1 (en) * 2000-05-24 2014-03-12 Otsuka Pharmaceutical Co., Ltd. Method of stabilizing preparation
RU2271351C1 (ru) * 2004-09-24 2006-03-10 ГОУ ВПО Белгородский государственный университет Способ получения лаурилсульфата натрия
JP4918630B1 (ja) * 2010-08-20 2012-04-18 中外製薬株式会社 ４環性化合物を含む組成物
CN105121536A (zh) * 2012-11-22 2015-12-02 赢创罗姆有限公司 由粉末组合物制备颗粒状产品的方法
CN103058894A (zh) * 2013-01-07 2013-04-24 东明俱进化工有限公司 一种高纯度十二烷基硫酸钠的生产方法
CN103520603B (zh) * 2013-10-11 2016-02-24 哈尔滨欧替药业有限公司 妇炎灵阴道膨胀栓及其制备方法和检测方法
CN103816545A (zh) * 2013-10-30 2014-05-28 安徽万邦医药科技有限公司 含有利福平和十二烷基硫酸钠的药物组合物
KR20220042486A (ko) 2014-04-25 2022-04-05 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
CN106456651A (zh) * 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
TWI718102B (zh) * 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
GR1009230B (el) * 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη
JP7233852B2 (ja) * 2018-04-17 2023-03-07 キョーリンリメディオ株式会社 変色が抑制された固形製剤
CN110146603B (zh) * 2019-04-19 2021-11-02 南通联亚药业有限公司 一种测定奥卡西平缓释片释放度的分析方法

Also Published As

Publication number Publication date
MX2022007786A (es) 2022-07-19
CN114786727A (zh) 2022-07-22
AU2020411954A1 (en) 2022-05-19
JPWO2021132541A1 (es) 2021-07-01
US20240100058A1 (en) 2024-03-28
IL293995A (en) 2022-08-01
BR112022007093A2 (pt) 2022-07-05
WO2021132541A1 (ja) 2021-07-01
CA3158342A1 (en) 2021-07-01
CN114786727B (zh) 2024-11-08
EP4082578A1 (en) 2022-11-02
EP4082578A4 (en) 2024-02-14
KR20220119605A (ko) 2022-08-30
TW202135827A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
Persakis et al. Cost of capital, audit and earnings quality under financial crisis: A global empirical investigation
Srivastava Why have measures of earnings quality changed over time?
Hua et al. How to leverage the role of social capital in pro-environmental behavior: A case study of residents’ express waste recycling behavior in China
Duo et al. A novel and accurate finite difference method for the fractional Laplacian and the fractional Poisson problem
CL2022002771A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y su uso (divisional de cl 201703195).
MX2021009967A (es) Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas.
CO2021012719A2 (es) Métodos para producción de células car-nk y uso de las mismas
CR20190199A (es) Anticuerpos anti-pd-1 y sus usos
EP4530350A3 (en) Improved flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting
BR112022010225A2 (pt) Transdução de car combinado em grande escala e edição de gene crispr de células nk
MX2021000934A (es) Linfocitos t que contienen nef y métodos para producirlos.
MX363588B (es) Tóner, revelador, aparato formador de imágenes y cartucho de proceso.
BR112020003467B8 (pt) Método para preparar uma composição fermentada, e, composição fermentada
MX2021013522A (es) Metodos de seleccion auxotrofica.
MX2018003036A (es) Metodo para producir celulas progenitoras renales.
AR121187A1 (es) Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene
NZ727182A (en) Methods for 2-color radiography with laser-compton x-ray sources
BR112017023508A2 (pt) processo para produção de uma composição de polímero reforçado com fibras, produto, e, uso de um tecido não tecido.
EP4116713A3 (en) Compositions, devices, and methods of osteoarthritis sensitivity testing
MX2022003461A (es) Metodos de produccion de composiciones de anticuerpos.
GB2561112A (en) Method of imaging defects using an electron microscope
WO2020067648A3 (ko) 수지상세포를 이용한 면역 소재의 면역증진 효과 평가방법 및 면역 소재 스크리닝 방법
EA201891356A1 (ru) Способ получения гранул
GB2565009A (en) Generating synthetic frame features for sentinel frame matching
AT522192A3 (de) Zusammensetzung und Verfahren zur Herstellung von optischen Linsen